Houston, United States
Alaunos Therapeutics is a pioneering force in the biotech sector, focusing on innovative solutions in the treatment of solid tumors through its proprietary Adoptive TCR-T cell therapy. The company's slogan, "Attacking solid tumors with TCRs," succinctly captures its mission-driven approach.
Founded in 2005 and headquartered in the United States, Alaunos capitalizes on its strategic location in Houston, TX, a city renowned for hosting the largest medical center in the world. This location, coupled with Texas's favorable business environment—characterized by no state income tax and reduced living costs—positions the company advantageously.
As a key player in the Biotechnology, Health and Wellness, and Pharmaceutical industries, Alaunos has made significant strides with its rapid, cost-effective solutions that directly address unmet clinical needs. Its last recorded financial milestone was a $15.70M Post-IPO Equity investment on November 29, 2022, underscoring strong investor confidence in its innovative trajectory.
